News Image

MedivirĀ“s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Provided By PR Newswire

Last update: May 23, 2024

STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. 

Read more at prnewswire.com

TANGO THERAPEUTICS INC

NASDAQ:TNGX (2/21/2025, 8:00:01 PM)

After market: 2.36 0 (0%)

2.36

-0.07 (-2.88%)



Find more stocks in the Stock Screener

Follow ChartMill for more